Skip to main content

Table 1 Inhibition of pp28-luciferase by anti-CMV compounds using plaque reduction or luciferase assay

From: Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors

Compound

Plaque Reduction EC50 (μM)

Luciferase

EC50 (μM)

Reference

FOS

328 +/- 28

268 +/- 20

[28]

Dimer Sulfone Carbamate

0.067 +/- 0.011

0.066 +/- 0.004

[18]

ART

8.03 +/- 0.55

6.74 +/- 0.38

[29]

GCV

4.39 +/- 0.39

4.23 +/- 0.27

[30]

CHX

0.262 +/- 0.067

0.299 +/- 0.036

NA

  1. EC50 was determined by plaque reduction assay or luciferase expression in pp28-luciferase CMV infected HFF cells. Reported values represent the means ± standard deviations (SD) of data derived from at least three independent experiments performed in duplicate. Historical controls are provided for EC50 values (reference column).